© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Sydney Jennings
Articles
MindMed Initiates Second Phase 3 Trial of Psychedelic MM120 for Generalized Anxiety Disorder
February 04, 2025
The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.
AI-Assisted Mammography Boosts Breast Cancer Detection by 29% in Large Study
February 04, 2025
Results from the MASAI clinical trial also showed that AI-assisted screening reduced screen-reading workload without increasing the rate of false-positives.
FDA Approves Monthly Lecanemab for Early-Stage Alzheimer Disease: Daily Dose
February 04, 2025
Your daily dose of the clinical news you may have missed.
Optimizing PTSD Treatment: The Role of Brexpiprazole and Sertraline in Future Guidelines
February 03, 2025
Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.
COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
February 03, 2025
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
Stool Tests Still Top Choice for CRC Screening: Daily Dose
February 03, 2025
Your daily dose of the clinical news you may have missed.
7 Drugs Approved for Primary Care: Q4 2024
January 31, 2025
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds
January 31, 2025
Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
January 31, 2025
Your daily dose of the clinical news you may have missed.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
January 30, 2025
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.